Kornimate/medical-research-clean huggingface dataset:
revisiting omental transposition in locally advance and locally recurrent breast cancer

Conditions: Survival Rate

Summary: locally advance breast cancer and extensive locoregional recurrence are still considered as complexity of reconstruction. although previous studies concluded that omental transposition was considerably indicated in poor vascularity in irradiated tissue, secondary infection and large defect become the obstacles of local tissue flaps. while some centres showed the excellent healing of omental transposition. meanwhile, many studies showed the preferable outcome in escalating radiotherapy in term of locoregional control. in the investigators' institute, omental transposition in breast cancer has been developed for twenty years. the only institute in thailand enhanced using this procedure in order to closure of large primary breast cancer and chest wall recurrence. this procedure is undertaken by single surgeon (dr. k.j.). the investigators' protocol of omental transposition is including preoperative chemotherapy, preoperative accelerated radiation up to 80 gy, approval of breast cancer centre committee, and meticulous wound care including vacuum assisted wound dressing, non-adhesive dressing. as a result, survival time could be improved.


Eligibility criteria:
inclusion criteria: * the patients with omental transposition operation within king chulalongkorn memorial hospital * more than 18 years of age exclusion criteria: * the patients with refusal
the effectiveness of a relaxation technique on the quality of life and symptoms in people living with hiv

Conditions: HIV

Summary: quality of life of people living with hiv is strongly affected by the presence of one or more symptoms, such as sleep problems, fatigue, muscle pain, anxiety and depressive symptoms. autogenic training has shown positive effects on these symptoms in different populations, but there is very little evidence on the effects of this relaxation technique in people living with hiv.

the aim of this project is to evaluate the effectiveness of a relaxation technique, autogenic training, on the quality of life and the physical and psychological symptoms in people living with hiv.

Eligibility criteria:
inclusion criteria: * being older than 18 ; * have a diagnosis of hiv; * present at least one of the following symptoms during the preceding two weeks: sleep problems, fatigue, pain, anxiety or symptoms of depression; * understand and speak french and; * be able to follow the instructions to learn the relaxation technique. exclusion criteria: -

Keywords: relaxation quality of life symptoms pain depression anxiety sleep problems fatigue
assessment of risk in chronic airways disease evaluation

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Summary: patients with chronic obstructive pulmonary disease (copd) have an increased risk of cardiovascular disease,osteoporosis, muscle wasting and diabetes mellitus. cardiovascular disease is a major cause of death in such patients and it may be related to excess stiffening of the walls of major arteries, such as the aorta, and it has been suggested to represent premature aging. however, there is little known of the development of these problems, which were previously considered to be due to smoking and which is now known not to be the only factor. the investigators will study a large group of patients with mild to very severe airflow obstruction based on the nice 2010 classification of severity and a matched comparator group free of copd. this study involves three assessments of the development of the complications of copd over a five year period. the key measure will be the rate of change in the aortic wall stiffness, an accepted indicator of the risk of heart disease. changes in wall stiffness will be related to the severity of lung disease; other known cardiovascular risk factors, such as high blood pressure, increased blood cholesterol and to cardiovascular events including heart attacks and death; and to the presence of other complications, such as osteoporosis, muscle wasting and diabetes mellitus. these measures will be analysed in the context of changes in bodywide inflammation and metabolic function and the changes in the rate of ageing. this increased knowledge of interacting factors in the complications of copd is likely to lead to studies of treatments to avoid their development.


Eligibility criteria:
inclusion criteria: * previously proven copd or at risk of developing copd exclusion criteria: * pregnancy * a history of malignancy in the last 5 years * unable to give informed consent or diagnosed dementia * renal or hepatic failure * active endocrine disorder eg., addison's disease, hypothyroidism * any other disease identified as having an inflammatory or metabolic component, eg. rheumatoid disease * disorders affecting mobility, eg. parkinson's disease, cerebrovascular accident.
pediatric resuscitation with feedback devices

Conditions: Cardiac Arrest

Summary: the aim of this study was to compare four different cpr feedback devices to standard bls in terms of the quality of single rescuer pediatric resuscitation. therefore, the investigators hypothesis was that there would be no difference between cpr methods in terms of chest compression quality parameters.

cardiac arrest is a leading cause of death worldwide. high-quality chest compressions are of paramount importance for survival and good neurological outcome. unfortunately, even health professionals have difficulty performing effective cpr. chest compression (cc) is often too shallow, compression ratio is inadequate, and hands-off time is too long. cpr feedback devices might be an option for rescuers to in order to increase cc efficiency.

Eligibility criteria:
inclusion criteria: * give voluntary consent to participate in the study * medical profession (nurses) exclusion criteria: * not meet the above criteria * wrist or low back diseases
evaluation of stigma toward patients with alopecia areata, atopic dermatitis, vitiligo, and psoriasis

Conditions: Psoriasis (PsO); Vitiligo Vulgaris; Atopic Dermatitis; Areata Alopecia

Summary: primary objective: the primary objective is to evaluate in the general population the difference between emotional reactions associated with facial involvement by four major dermatologic diseases: psoriasis, atopic dermatitis, vitiligo, and alopecia areata. * compare the social distance and stereotyping by the general population toward individuals with facial involvement by: psoriasis, atopic dermatitis, vitiligo, and alopecia areata. * evaluate demographic factors that describe a greater tendency toward stigmatization.

basic demographic characteristics (gender, age, employment status, education level) will be recorded for each patient. participants will be asked to observe images depicting faces of individuals with atopic dermatitis, alopecia areata, vitiligo, and psoriasis (generated through artificial intelligence systems). they will be asked to select the individual from those shown that generates the most compassion/pity, disgust, blame/disapproval/disdain, and curiosity for them, analyzing the same emotional responses investigated in a study on stigma toward psoriasis patients. in addition, each participant will be given a 14-question questionnaire on stigma (analyzing social distance and stereotyping) toward one of the four diseases under investigation (psoriasis, atopic dermatitis, vitiligo, or alopecia areata), selected randomly. for each question, responses will be expressed from 1 to 5, on a likert scale, with lower scores indicating greater stigma. (total score between 14 and 70)

Eligibility criteria:
inclusion criteria: * -patients aged\>18 years, both sexes; * signature of written informed consent; exclusion criteria: * patients diagnosed with psoriasis, atopic dermatitis, vitiligo or alopecia areata. * patients with first-degree relatives with psoriasis, atopic dermatitis, vitiligo or alopecia areata * those who for professional or personal reasons have direct knowledge of the diseases in question.
vascular effects of regular cigarettes versus electronic cigarette use

Conditions: Vascular Diseases

Summary: the purpose of this study is to assess the effects of electronic cigarettes-nicotine and electronic cigarette-nicotine free on endothelial function as compared to traditional cigarettes. due to ethical reasons, we cannot fully randomise all particpants to the three arms. participants who wish to quit smoking will be randomized to 1. switch to electronic cigarettes containing nicotine plus flavor 2. switch to electronic cigarettes containing flavor alone those who do not wish to quit smoking will continue on the tobacco cigarette arm treatment period will be 28 days

electronic cigarettes (ec) are gaining popularity as an alternative to traditional cigarettes (tc). despite not containing all the harmful substances seen in tc, ec are known to contain impurities that may have a detrimental impact on human health. the effects of ecs compared with tc on vascular function, inflammation and oxidative stress are unknown. it is increasingly recognised that nicotine itself has significant atherothrombotic effects. therefore, clinicians are unable to confidently recommend ecs as a less risky alternative to tc. hypothesis: endothelial function will be improved on ec compared to tc when measured by flow mediated dilatation (fmd). potential benefit: this study will provide further information on the potential use these devices and the risks and/or benefits associated with them, specifically in relation to vascular health.

Eligibility criteria:
inclusion criteria: * aged 18 years and over * currently smoking ≥15 full strength tobacco cigarettes per day for at least 2 years, or roll-up tobacco equivalent (cigar or pipe smokers not included). * willing to stop tobacco cigarettes for period of study if required * willing not to use electronic cigarettes if required * able to give informed consent exclusion criteria: * pregnant or lactating. * women of childbearing potential who do not abstain from sex or use effective contraception. * on current prescribed medication for cardiovascular disease. * history of cardiovascular disease (excluding hypertension), diabetes, active malignance or chronic renal disease. * nut allergy * participation in another clinical trial (other than observational trials and registries) with an investigational product and/or intervention within 30 days before visit 1.
a bioequivalence study of l04td1 compared to administration of l04rd1 in healthy volunteers

Conditions: Healthy

Summary: this is a randomized, open, single-dose, crossover-design, phase 1, single-center study to evaluate bioequivalence after administration of l04rd1 or administration of l04td1 in healthy volunteers.


Eligibility criteria:
inclusion criteria: * a subject who weighs 50 kg or more at the screening visit and has a body mass index (bmi) of 18.0\~29.9 kg/m2 * a subject who is judged to be eligible to participate by the results of screening tests (vital signs, clinical laboratory tests, 12-lead ecg, etc.) by the principal investigator within 30 days before the first administration of the investigational drug * a subject and their partner who agree to use a medically appropriate method of contraception to exclude potential of pregnancy and not to provide sperm or ova from the first dose to 28 days after the last dose of the investigational drug * a subject who voluntarily signs the consent form after hearing and understanding the purpose and content of this study, thge characteristics of the investigational drugs, expected adverse reactions, and etc. exclusion criteria: * a subject who has a history or present symptoms of clinically significant liver, kidney, nervous system, respiratory system, digestive system, endocrine system, blood/tumor, urinary system, cardiovascular system, musculoskeletal disease, or psychiatric disease * a subject who has an acute illness within 30 days prior to the first dose of investigational drug * a subject who has a history of gastrointestinal surgery that may affect drug absorption (except simple appendectomy or hernia surgery) or has gastrointestinal diseases * a subject who has taken drugs that induce or inhibit drug metabolizing enzymes such as barbiturates within 1 month prior to the first administration * a subject who has participated in other clinical trials or bioequivalence studies within 6 months prior to the first dose of the investigational drug * a subject who is judged unsuitable to participate in this study by the principal investigator
alteplase through an indwelling pleural catheter for the management of symptomatic septated malignant pleural effusion

Conditions: Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm

Summary: this study investigates whether alteplase can help to improve pleural fluid drainage and dyspnea (breathlessness) in patients with non-draining malignant pleural effusion. alteplase helps dissolve blood clots and is used to treat heart attacks, strokes, and clots in the lungs. alteplase may help to control symptoms of breathlessness.

primary objective: i. to evaluate dyspnea using the visual analog scale (vas) scale at one week in patients with symptomatic septated malignant neoplasm of the pleural effusion (mpe) and a non-draining/inadequately draining indwelling pleural catheter (ipc). secondary objective: i. to evaluate dyspnea using the visual analog scale (vas) scale at 48 hours (+/-12 hours) after treatment with intrapleural alteplase, in patients with septated mpe and a nondraining/inadequately draining ipc. in addition, complications, quality adjusted survival (calculated using the sf-6d to determine utilities and then integrating utilities over time to arrive at quality-adjusted survival), change in dyspnea (using the borg score and vas scale) at 1 week (+/- 1 day), 2 weeks (+/- 2 days) and every 4 weeks (+/- 2 days) after the intervention until ipc removal or death. outline: patients are randomized to 1 of 2 arms. arm i: patients receive alteplase instilled into the ipc which is capped for 1-2 hours before the catheter is drained. arm ii: patients receive placebo instilled into the ipc which is capped for 1-2 hours before the catheter is drained. beginning 1 week later, patients may receive alteplase as in arm i.

Eligibility criteria:
inclusion criteria: * referral to pulmonary services for inability to drain fully via ipc * presence of a symptomatic septated pleural effusion * a pleural effusion of significant moderate to large volume based on: * chest radiograph: effusion filling \>= 1/3 of the hemithorax, or * computed tomography (ct)-scan: ap depth of the effusion \>= 1/3 of the ap dimension on the axial image superior to the hemidiaphragm, including atelectatic lung surrounded by effusion, or * ultrasound: effusion spanning at least three intercostal spaces, with a \>= 3 cm in at least one intercostal space, while the patient sits upright * age \> 18 * borg score \>= 3 * absence of a blocked ipc as demonstrated by a flush with 20 cc of saline x1 without resistance * presence of septated effusion based on ultrasound (us) and chest ct exclusion criteria: * inability to provide informed consent * study subject has any disease or condition that interferes with safe completion of the study including: * uncorrectable coagulopathy based on criteria followed by cardiopulmonary center for procedures. * active bleeding * known allergic reaction to thrombolytics * pleural effusion is smaller than expected on bedside pre-procedure ultrasound * no septations and/or no loculations on bedside pre-procedure ultrasound * patient is asymptomatic * blocked ipc as determined by saline flush
hyperglucagonaemia in patients with type 2 diabetes - role of glucagon clearance

Conditions: Diabetes

Summary: the study aims to evaluate the elimination and degradation of glucagon in patients with type 2 diabetes compared to matched healthy subjects.

in the present project the investigators wish to identify whether the elimination and degradation of glucagon differ between healthy control subjects and patients with type 2 diabetes. furthermore, the investigators wish to examine whether obesity is an independent factor for altered glucagon metabolism. thus, by examining glucagon elimination in obese subjects with and without type 2 diabetes and in lean subjects with and without type 2 diabetes the investigators will be able to describe the metabolic clearance rate (mcr) of glucagon in a broad spectrum of individuals with different levels of insulin resistance and beta cell dysfunction.

Eligibility criteria:
inclusion criteria: patients with type 2 diabetes * caucasians above 35 years of age with diet or/and metformin-treated type 2 diabetes of at least 3 month duration (diagnosed according to world health organization (who) criteria * bmi either below 27 or above 33 kg/m\^2 * normal haemoglobin * informed consent subjects with ngt * caucasians above 35 years of age * bmi either below 27 or above 33 kg/m\^2 * normal hba1c (according to who criteria) * normal haemoglobin * informed consent exclusion criteria: patients with type 2 diabetes * inflammatory bowel disease * operation within the last 3 months * severe kidney disease (egfr \< 60 ml/min) * severe liver disease (serum alanine aminotransferase (alat) and/or serum aspartate aminotransferase (asat) \>2×normal values) * pregnancy and/or breastfeeding * age above 80 years * any condition that the investigators feel would interfere with trial participation subjects with ngt * diabetes * prediabetes (impaired fpg or hba1c above 42 mmol/mol) * first-degree relatives with diabetes * inflammatory bowel disease * intestinal resection * severe kidney disease (egfr \< 60 ml/min) * liver disease (ala t and/or serum asa t \>2×normal values) * pregnancy and/or breastfeeding * age above 80 years any condition that the investigators feel would interfere with trial participation

Keywords: diabetes glucagon metabolic clearance rate of glucagon
quantifying the epidemiological impact of targeted indoor residual spraying on aedes-borne diseases

Conditions: Aedes-borne Diseases; Dengue; Chikungunya; Zika

Summary: the trial will be conducted in the city of merida extending ongoing longitudinal cohort to follow a population of 4,600 children 2-15 years old randomly allocated to receive either tirs treatment or not. if efficacious, tirs will drive a paradigm shift in aedes control by: considering ae. aegypti behavior to rationally guide insecticide applications; the change to preventive control (pre- abd transmission season rather than in response to symptomatic cases); the use of third generation insecticides to which ae. aegypti is susceptible.

contemporaneous urban vector control (truck-mounted ultra-low volume spraying, thermal fogging, larviciding) has failed to contain dengue epidemics and to prevent the global range expansion of aedes-borne diseases (abds: dengue, chikungunya, zika). part of the challenge in sustaining effective abd control emerges from the remarkable paucity of evidence about the epidemiological impact of any vector control method. furthermore, the classic deployment of interventions in response to clinical cases fails to account for the important contribution of out-of-home human mobility and asymptomatic infections. the trial will be conducted in the city of merida extending ongoing longitudinal cohort to follow a population of 4,600 children 2-15 years old randomly allocated to receive either tirs treatment or not. if efficacious, tirs will drive a paradigm shift in aedes control by: considering ae. aegypti behavior to rationally guide insecticide applications; the change to preventive control (pre- abd transmission season rather than in response to symptomatic cases); the use of third generation insecticides to which ae. aegypti is susceptible.

Eligibility criteria:
inclusion criteria: 1. household level inclusion criteria: * household is located within the bounds of a study cluster (5x5 city-block clusters) * city block has at least 60% premises that are residential 2. individual level inclusion criteria: * 2 or more and up to 15 years of age at the time of initial enrollment * living in a house that consented to tirs exclusion criteria: 1. household level exclusion criteria: * households where study personnel identify a security risk (i.e., site where drugs are sold, residents are always drunk or hostile) * sites where no residents spend time during the day (i.e. work 7d a week outside the home) * inability for a resident to provide informed consent * non-residential places (e.g., businesses, schools, markets, etc.) 2. individual level exclusion criteria: * less than 2 years of age or more than 15 years of age at the time of enrollment * not living in a house that consented to tirs * having a medical condition that prevents implementation of study procedures * temporary visitor to household * plans to leave study area within next 12 months

Keywords: targeted indoor residual spraying children denv chikv zikv ae. aegypti mosquito
clinical investigation of a new intraocular lens

Conditions: Cataract

Summary: the purpose of this clinical trial is to evaluate the safety and effectiveness of the tecnis symfony extended range of vision iol.


Eligibility criteria:
inclusion criteria: * minimum 22 years of age * bilateral cataracts for which phacoemulsification extraction and posterior iol implantation have been planned for both eyes * preoperative best corrected distance visual acuity (bcdva) of 20/40 snellen or worse with or without a glare source * potential for postoperative bcdva of 20/30 snellen or better * corneal astigmatism * clear intraocular media, other than cataract * availability, willingness and sufficient cognitive awareness to comply with examination procedures * signed informed consent and hipaa authorization * ability to understand and respond to a questionnaire in english or spanish exclusion criteria: * requiring an intraocular lens power outside the available range of +16.0 d to +28.0 d * pupil abnormalities * recent ocular trauma or ocular surgery that is not resolved/stable or may affect visual outcomes or increase risk to the subject * prior corneal refractive or intraocular surgery * corneal abnormalities * inability to achieve keratometric stability for contact lens wearers * subjects with diagnosed degenerative visual disorders that are predicted to cause visual acuity losses to a level of 20/30 snellen or worse during the study * subjects with conditions associated with increased risk of zonular rupture, including capsular or zonular abnormalities that may lead to iol decentration or tilt, such as pseudoexfoliation, trauma, or posterior capsule defects * use of systemic or ocular medications that may affect vision * prior, current, or anticipated use during the course of the 6-month study of tamsulosin or silodosin, that may, in the opinion of the investigator, confound the outcome or increase the risk to the subject * inability to focus or fixate for prolonged periods of time * poorly-controlled diabetes * acute, chronic, or uncontrolled systemic or ocular disease or illness that, in the opinion of the investigator, would increase the operative risk or confound the outcome(s) of the study. * may be expected to require retinal laser treatment or other surgical intervention during the course of the study * patient is pregnant, plans to become pregnant, is lactating or has another condition associated with the fluctuation of hormones that could lead to refractive changes * concurrent participation or participation within 30 days prior to preoperative visit in any other clinical trial * desire for monovision correction